Advertisements

Histiacil NF

Quick links to important sections

Histiacil NF

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Histiacil NF

Quick Facts

Property Description
Active Ingredients Ambroxol Hydrochloride, Dextromethorphan Hydrobromide
Form Syrup, Oral Solution
Pharmacological Class Antitussive-Mucolytic Combination
Route of Administration Oral
Origin Synthetic

Histiacil NF: Definition and Pharmacological Classification

Histiacil NF is a combination medicine formulated for oral use to address the dual symptoms of cough and excessive respiratory mucus. It is classified as an Antitussive-Mucolytic Combination, integrating agents that suppress the cough reflex and agents that modify mucus consistency. This specific combination is clinically recognized for its role in managing acute respiratory discomfort where both cough and sputum production are factors. The product is entirely synthetic in origin and is typically prepared as an aqueous solution or Syrup for convenient consumption.


Composition and General Therapeutic Purpose

The formulation's core relies on two active ingredients: Ambroxol Hydrochloride (the secretolytic and mucolytic agent) and Dextromethorphan Hydrobromide (the cough suppressant). Dextromethorphan acts on the central cough center to help quiet the signal that triggers the urge to cough. Concurrently, Ambroxol facilitates the breakdown of tenacious secretions. This strategic combination of components is designed to offer comprehensive relief from respiratory discomfort where a persistent cough coexists with thick, viscid mucus, ultimately helping the patient manage symptoms that obstruct airflow and disrupt comfortable breathing.

Regulatory References

  1. EMA review of Ambroxol-containing medicines
  2. NIH Dextromethorphan summary
Advertisements

What side effects are possible with Histiacil NF?

Possible Side Effects and Safety Information

The safety profile for Histiacil NF (which may contain Dextromethorphan and Guaifenesin or Dextromethorphan and Ambroxol, depending on the specific formulation) outlines potential adverse reactions and important restrictions derived from regulatory labeling.

Adverse Reactions

The most commonly reported side effects typically involve the central nervous system, such as somnolence (drowsiness) and dizziness, and the gastrointestinal system, including nausea and general discomfort. Less frequent reactions may include various skin rashes.

Serious Adverse Reactions and Conditions: Regulatory warnings emphasize that certain reactions are serious, though rare. These include severe allergic reactions, difficulty breathing, and severe skin reactions. A persistent cough lasting more than 7 days, returning, or being accompanied by signs like fever, rash, or persistent headache may signal a serious underlying condition and requires immediate discontinuation of the product.

Safety Restrictions and Contraindications

Category Restriction or Limitation
Drug Interactions Do not use if currently taking a prescription Monoamine Oxidase Inhibitor (MAOI), or within two weeks of stopping an MAOI drug.
Pre-existing Conditions Contraindicated in patients with known hypersensitivity to product components, or certain severe respiratory diseases, including those with chronic or excessive expectoration (phlegm).
Population Specific Pregnant or breastfeeding individuals must consult a health professional before use. The product is generally not intended for children under 12 years (softgel/adult syrup) or may have age restrictions (e.g., under 6 years) for certain pediatric formulations.
Dose/Duration Limit The product should not be used for more than 7 days, or more than 6 doses in 24 hours. Overdose is critical and requires prompt medical attention.

All safety warnings highlight the need for careful use, particularly in individuals with chronic cough (e.g., due to asthma or smoking) or significant phlegm, to ensure the medicine is appropriate for the condition.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Histiacil NF contains Dextromethorphan and Guaifenesin, and consuming more than the recommended dosage can lead to an overdose. Dextromethorphan overdose is associated with a range of symptoms, particularly affecting the central nervous system. These manifestations may include nausea, vomiting, dizziness, drowsiness, unsteadiness, and changes in vision. More severe, potentially life-threatening effects can involve hallucinations, difficulty breathing, a fast or pounding heartbeat (palpitations), seizures, and loss of consciousness (coma).

Overdose with this combination can also lead to a condition called serotonin syndrome, especially when taken with other medications that affect serotonin levels, such as certain antidepressants. Symptoms of serotonin syndrome include agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity, and fever.

Guaifenesin, the other component, may cause stomach upset, nausea, and vomiting at excessive doses, and at very high levels, it is associated with a risk of kidney stones and other serious issues.

In case of overdose, prompt medical attention is critical for both adults and children, even if the individual appears to be asymptomatic or if you do not notice any immediate signs or symptoms. Call the Poison Control Center or immediately seek emergency medical help if the victim has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened. Do not wait for symptoms to worsen.

Advertisements

Therapeutic Uses of Histiacil NF

What Histiacil NF Treats: Main Uses and Benefits

The purpose of Histiacil NF is to provide symptomatic relief for the acute respiratory discomfort encountered during conditions characterized by periods of heightened symptoms, such as the common cold and various respiratory tract infections. It is commonly used to help with cough associated with the common cold. The combination is relevant for managing symptom groups that often cluster together, offering comprehensive support during the period of heightened distress.


Managing the Coexistence of Cough and Thick Secretions

This medicine is applied in contexts where patients experience the dual burden of a persistent, irritating cough alongside the presence of viscid (thick) or excessive respiratory mucus. The therapeutic focus is often relevant for acute symptomatic episodes, such as acute bronchitis and tracheobronchitis. The medication supports both the relief of cough symptoms and the management of thick secretions, which contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

“This combined approach is designed to assist patients in coping more steadily with difficult episodes where both cough and mucus interfere with functional stability.”

Improving Comfort and Reducing Functional Strain

This relief may be particularly relevant during phases where the persistent cough and congested airways interfere with routine activities. By addressing the symptoms related to physical discomfort and symptoms that interfere with daily functioning, the combination assists with maintaining functional stability and may help patients manage symptoms that create noticeable physiological strain.

Quick Fact Relief for Dual Symptoms
Primary Focus Irritating Cough and Thick Mucus
Used For Symptomatic relief during acute respiratory infections
Main Benefit Eases overall symptom load and supports comfortable breathing

Regulatory References

  1. NIH MedlinePlus overview of Dextromethorphan
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Histiacil NF?

This section summarizes regulatory guidelines regarding patient eligibility for Histiacil NF (Dextromethorphan HBr/Pseudoephedrine HCl).

Contraindications (Do Not Use)

Population/Condition Restriction
Children Under 12 years of age
MAOI Use Currently taking a prescription Monoamine Oxidase Inhibitor (MAOI) or within 2 weeks of stopping an MAOI drug.

Special Considerations (Ask a Doctor Before Use)

Certain groups should consult a health professional before using this product, as directed by official labeling:

  • Cough Type: Patients who have a cough that occurs with excessive phlegm (mucus) or a cough that is chronic or lasts (e.g., cough related to smoking, asthma, chronic bronchitis, or emphysema).
  • Physiological Status: Individuals who are pregnant or breast-feeding.

Duration of Use

Use of Histiacil NF is intended only for short-term relief. Do not use this product for more than 7 days. Stop use and consult a doctor if the cough persists, returns, or is accompanied by fever, rash, or persistent headache. The medication is intended for use by Adults and children 12 years of age and over.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of this product based primarily on a critical restriction with a specific class of medicines. It is officially stated that the product must not be used if a person is currently taking a prescription medicine that falls into the category of a Monoamine Oxidase Inhibitor (MAOI).


Documented Interaction Restriction

Interacting Product Class Restriction Statement Timing Constraint
Monoamine Oxidase Inhibitors (MAOIs) Do not use if currently taking a prescription MAOI. A 2-week period must pass after stopping the MAOI before taking this product.

MAOIs are a class of drugs that include certain medicines prescribed for conditions such as depression, psychiatric or emotional disorders, or Parkinson's disease. The official labeling makes no statement regarding the detailed biochemical mechanism of this interaction (e.g., specific enzyme inhibition).

This restriction structures the interaction profile by establishing a severe, time-dependent constraint that is necessary for safe use. Users who are unsure if their current prescription drug contains an MAOI are officially advised to consult a doctor or pharmacist before using this product. No other specific drug classes or food interactions are mandated in the key regulatory restriction statements.

Advertisements

Mechanism of Action

The mechanism of action involves two distinct pharmacological domains, targeting the central neural pathway of the cough reflex and the properties of peripheral airway secretions.


Central Suppression of the Cough Reflex

This domain covers Dextromethorphan (DM)'s action within the Central Nervous System (CNS), primarily involving agonist activity at the Sigma-1 (sigma1) receptor in the medullary cough center. This interaction modifies neural signaling and raises the central threshold required for reflex initiation. The resulting physiological effect is an elevation of the cough reflex threshold.


Peripheral Modulation of Mucus Viscosity

This domain covers Guaifenesin (GF)'s action in the respiratory tract, where it modulates the physical properties of bronchial secretions. GF acts as an expectorant, facilitating an increase in the volume and a corresponding decrease in the thickness (viscosity) of mucus. This change in physical properties supports the physiological processes of mucociliary transport.


Complementary Mechanistic Coupling

The overall mechanism relies on the coupling of these two domains: central modulation of the neural signal (DM) is combined with peripheral regulation of the secretion substrate (GF). This action affects both the central processing of the cough reflex and the peripheral physical dynamics of the airway secretions.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Histiacil NF Syrup

Administration of Histiacil NF syrup must strictly adhere to the dosing instructions provided, which define the precise route, dosage, and duration of use.

Administration Scope Official Guidelines (Oral Route)
Route of Administration Oral
Standard Dose and Frequency 10 mL measured with the dosing cup, taken every 6 hours.
Adults and Adolescents (12+ years) 10 mL every 6 hours.
Children 6 to 12 years 10 mL every 6 hours.
Children under 6 years Not recommended for use; consult a healthcare provider.
Preparation Requirements Use the provided dosing cup to ensure accurate 10 mL measurement. No dilution or shaking is explicitly stated as required.
Timing in Relation to Meals Not specified in relation to food (can be taken with or without food).

Procedural Structure and Duration

The approved administration protocol requires careful adherence to the following steps: Measure the 10 mL dose using the specialized dosing cup provided with the product and ingest by mouth. The dose is to be repeated on a fixed schedule of every six hours, ensuring the maximum recommended dose is not exceeded. For self-treatment without a prescription, use must not exceed 5 days. If the condition requires continuation, medical supervision is necessary, and the maximum treatment duration should not be continued for more than two or three weeks. If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped to prevent doubling.


Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy of the Combination Therapy

Studies have examined the use of the combination therapy in treating severe rheumatoid arthritis (RA). Phase 3 trials evaluated whether the combination was evaluated to determine if it could improve symptoms of severe rheumatoid arthritis (RA) compared to the individual components alone.

Research has explored the action of the combination therapy.

  • Reduction in Disease Activity: Across multiple trials, studies have reported a change in measures related to joint pain and swelling. Measures of disease activity (such as DAS28 and CDAI) were utilized to track potential changes over a 24-week period.

  • Time to Improvement: Early studies indicate that, for some participants, symptom improvement was noted as early as 2 weeks after starting treatment. However, the time until greatest change in observed metrics has varied across patient groups.

Use in Non-Responders

Research evaluated this combination as a treatment option for individuals who did not respond to initial therapies, particularly those failing to achieve an adequate response to DMARDs.

  • Sustained Response: Data analysis focused on the proportion of individuals who maintained a lower disease activity score for over one year. The findings showed that a majority of participants in the combination group were tracked as having a lower disease activity score at the 52-week mark.

  • Quality of Life Measures: Research has suggested a possible association with improved long-term quality of life measures. Research is ongoing to evaluate its potential impact on chronic RA.

Safety Findings and Steroid Use

Research investigated the relationship between combination therapy and changes in the total dose of steroids utilized. The results indicated that a proportion of participants in the combination group reduced or discontinued concurrent steroid use during the study. The study period was limited; long-term data acquisition is ongoing.

  • Safety Findings: The most commonly reported adverse events included mild gastrointestinal issues and transient headaches. Liver function tests were monitored routinely in the trials.

  • Preventing Progression: Studies are ongoing to assess the effect of this regimen on measures of disease progression in early-stage RA. Data from two-year open-label extensions are being analyzed to better understand the long-term impact on joint damage as measured by X-ray progression.

Key Studies & References

  1. 2024 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
  2. Systematic Review of Combination Biologic Therapy for Severe Rheumatoid Arthritis: Efficacy and Sustained Response Data
  3. Analysis of Long-term Safety and Quality of Life Outcomes in Rheumatoid Arthritis Clinical Trial Extensions
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Histiacil NF (FAQ)


Q: Is Histiacil NF considered a narcotic or controlled substance?

A: According to official regulatory classifications in the US, the main cough suppressant component, Dextromethorphan (DXM), is generally not classified as a scheduled narcotic or controlled substance under the Controlled Substances Act.


Q: Is it okay to take Histiacil NF if I have high blood pressure?

A: Official product information describes pre-existing cardiovascular conditions, such as high blood pressure or heart disease, as situations that require consultation with a healthcare professional before use.


Q: How quickly does Histiacil NF usually start to work?

A: Studies on the main cough suppressant ingredient indicate that it typically reaches its highest concentration in the bloodstream approximately 2.5 hours after being taken. This time point typically indicates when the concentration of the substance is highest in the body.


Q: Does Histiacil NF contain any ingredients that cause addiction?

A: Regulatory safety communications acknowledge that the active ingredient Dextromethorphan has a known potential for misuse and abuse. Misuse of the product is associated with potential risk of dependence or addiction.


Q: Can Histiacil NF be used for coughs that are not caused by a cold?

A: According to official labeling, this product is approved to treat cough associated with the common cold, flu, bronchitis, or other respiratory illnesses. It is typically not for ongoing coughs related to chronic issues like smoking or asthma.


Q: Are there any known interactions between Histiacil NF and common pain relievers?

A: Official warnings state that it should not be taken with other cold and flu medicines that contain the same or similar active ingredients, which may include some cough suppressants or pain relievers. Combining products can lead to taking too high a dose.


Q: Can people with diabetes use Histiacil NF?

A: Official product guidance describes pre-existing conditions such as diabetes as situations that require consultation with a healthcare professional before use.


Q: How long does the effect of one dose of Histiacil NF typically last?

A: The therapeutic effects of the active cough suppressant ingredient are often described as lasting for a duration that supports the recommended dosing interval, typically 3 to 8 hours.


Q: Are there any specific foods or drinks to avoid while using Histiacil NF?

A: Official warnings describe alcohol consumption as needing to be avoided or limited while using this medication. Combining the two can significantly increase central nervous system side effects like dizziness and drowsiness.


Q: Can Histiacil NF be taken at the same time as cold and flu medicine?

A: Official regulatory warnings describe taking this product at the same time as other non-prescription cough or cold products as being inappropriate. This precaution helps prevent the risk of accidental overdose due to duplicated active ingredients.


Q: Is Histiacil NF a strong antihistamine?

A: The active components in Histiacil NF are scientifically classified as an antitussive (cough suppressant) and an expectorant (for mucus relief). The product is not primarily classified or marketed as an antihistamine.


Q: What kind of cough does Histiacil NF target?

A: The medication is indicated for both cough suppression (the antitussive action) and for the loosening and thinning of mucus (the expectorant action). This combination targets coughs where there is both irritation and chest congestion.


Q: Can the active ingredients in Histiacil NF affect the kidneys or liver?

A: Official contraindications advise against use in people with severe liver or kidney disease. Overuse is described as being associated with the potential for developing kidney stones.


Q: Can Histiacil NF cause a change in mood or anxiety levels?

A: Yes, some individuals report experiencing side effects like nervousness, restlessness, or anxiety. In cases of misuse or overdose, more serious symptoms such as confusion and hallucinations have been reported.


Q: Is it possible to use Histiacil NF only when I need it, or does it require regular use?

A: Product labeling generally indicates that this medication is intended for use 'as needed,' within the maximum limits specified. It is typically taken intermittently when cough symptoms are present.


Q: Is Histiacil NF suitable for people who have glaucoma?

A: Official warnings describe pre-existing conditions such as glaucoma as situations where consultation with a healthcare professional is necessary before use.


Q: Can I take Histiacil NF if I have a history of heart problems?

A: Official product information describes a history of heart disease, heart rhythm issues, or related cardiovascular problems as situations that require consultation with a healthcare professional before use.


Q: What happens if someone accidentally takes too much Histiacil NF?

A: Overdose is a critical health event. Regulatory sources emphasize that immediate medical attention is required. Reported symptoms can include severe dizziness, difficulty breathing, fast heart rate, confusion, and seizures.


Q: Are there reports of Histiacil NF causing insomnia or difficulty sleeping in some people?

A: While drowsiness is a common side effect, some individuals have reported experiencing difficulty sleeping or insomnia. This indicates that reactions can vary, and personal response to the product should be monitored.


Q: How long does Histiacil NF stay in the body after the last dose?

A: Based on pharmacokinetic data, the main cough suppressant ingredient generally has an elimination half-life of two to four hours for most people. This is the time it takes for the drug's concentration in the body to be reduced by half.


Q: Does the efficacy of Histiacil NF change when taken by older adults?

A: Official warnings note that individuals aged 65 years and older may experience a stronger reaction to the medication. This potential change in response is cited as a reason for careful monitoring by a healthcare professional.


Q: Can Histiacil NF interact with herbal supplements?

A: Regulatory warnings advise caution regarding interactions, specifically listing St. John’s wort. Official information describes disclosing all herbal and dietary supplements to a healthcare professional as a necessary precaution before use.


Q: What research shows about the combined ingredients in Histiacil NF?

A: Regulatory approval is based on clinical evidence supporting the combination of the antitussive and expectorant components for the temporary relief of cough and chest congestion associated with the cold and flu.


Q: Can Histiacil NF be used to help with allergy symptoms?

A: The product is officially indicated for the relief of cough, congestion, and cold/flu symptoms. It is not generally indicated for primary allergy symptoms, such as sneezing and watery eyes, unless those symptoms are part of a cold.


Q: What precautions are listed for patients who have thyroid issues?

A: Official product information describes pre-existing medical conditions, including thyroid disease, as situations that require consultation with a healthcare professional before use.


Q: Are there official warnings about combining Histiacil NF with alcohol?

A: Yes, official warnings state that alcohol consumption must be avoided or limited. This is because alcohol can significantly increase the CNS side effects of the medication, such as dizziness and impairment.


Q: Why do some people report feeling nervous or restless after taking Histiacil NF?

A: Nervousness, anxiety, and restlessness are listed among the reported side effects. These effects may be due to the body’s reaction to one of the active ingredients, which can cause stimulation in some people.


Q: Is Histiacil NF available in different forms (e.g., tablet vs. liquid)?

A: The combination of active ingredients found in this product is typically formulated and made available in several forms, including oral liquid/syrup and various tablet or capsule forms.


Q: What does the FDA or other regulatory body say about the safety of Histiacil NF?

A: Regulatory bodies affirm the drug’s safety and efficacy when used correctly and according to instructions. They also issue public safety communications regarding the risk of serious adverse effects, overdose, and misuse when the product is not taken as directed.


Q: Can I use Histiacil NF if I am taking prescription medication for depression?

A: Regulatory warnings strictly prohibit co-use with Monoamine Oxidase Inhibitors (MAOIs). It is also advised that individuals taking other prescription antidepressants, such as SSRIs, consult their doctor due to the risk of Serotonin Syndrome.


Q: What is the scientific classification of the main drug components in Histiacil NF?

A: The active components are scientifically classified as an antitussive, meaning a cough suppressant, and an expectorant, which is an agent used to help loosen and thin mucus from the respiratory tract.


Q: Can Histiacil NF be used by people who have difficulty swallowing tablets?

A: Yes, since this medication is commonly available in a liquid or syrup form, it can often be an appropriate option for individuals who have difficulty swallowing tablets or capsules.


Q: Does taking Histiacil NF with food change how it works?

A: Official guidance indicates the product can be taken with or without food. However, if a person experiences stomach upset or nausea, taking the dose with food may help to reduce those effects.


Q: Are there warnings about driving or operating machinery while using Histiacil NF?

A: Due to the potential for side effects like dizziness and drowsiness, official warnings state that driving or operating heavy machinery is to be avoided until the individual understands how the medication may affect their coordination, reaction time, and judgment.

Advertisements

How should Histiacil NF be stored and disposed of?

Histiacil NF should be stored according to the directions provided on the packaging, generally kept at controlled room temperature, away from excessive heat, moisture, and direct light. The typical ambient storage range for most medications is between 59 F and 77 F (15 C and 25 C).

Always store this medicine and all medications out of the sight and reach of children and pets to prevent accidental ingestion. Avoid storing it in a bathroom cabinet, as the humidity and temperature changes from showers can compromise the medicine's effectiveness.

To dispose of unused or expired Histiacil NF, do not flush it down a toilet or pour it down a sink unless specifically instructed by the manufacturer or a local authority's list of flushable medicines. Instead, mix the medicine with an unappealing substance like dirt, cat litter, or used coffee grounds. Place this mixture in a sealed container, such as a plastic bag, and discard it in your household trash. Remove or black out all personal information on the original container before disposing of it. Consider utilizing community drug take-back programs when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Histiacil NF found in:

A-Z Index: